Diagnostic value comparison of the combination of prostate-specific membrane antigen-body PET/MR and the prostate health index with each alone in early diagnosis of prostate cancer.

ABSTRACT:

Objective

This study aimed to figure out whether the combination of the prostate health index (PHI) and prostate-specific membrane antigen (PSMA)-PET/MR could improve the diagnostic accuracy for prostate cancer (PCa) than that of each individual method used alone.

Methods

In this prospective, observational study, 41 patients who underwent the systematic prostate biopsy between June 2019 and September 2022 were enrolled. Both the PHI test and ¹⁸F-PSMA-1007-PET/MR were performed prior to biopsies. The diagnostic accuracy of different models was compared by logistic regression, areas under the curve (AUCs) of the receiver operating characteristic, and net reclassification index (NRI).

Results

Among the 41 patients, 14 (34.1%) were pathologically diagnosed with

SUBMITTER: Liu J 

PROVIDER: S-EPMC11551469 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature